Stocktwits on MSN
SLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approval
The CEO reaffirmed confidence in the Phase 3 Regal trial evaluating GPS in AML, despite the study remaining blinded. ・Sellas expects clinical updates and Phase 2 readouts for its CDK9 inhibitor, ...
LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...
Retail Banker International on MSNOpinion
Validating AI-driven AML outcomes under FCA supervision
Dr Janet Bastiman discusses the future of AI for AML and offers expert guidance on how best to collaborate with the FCA and ...
A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C. The evaluation of Annamycin in combination with Ara-C (cytarabine) has ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
On April 7, 2026, the U.S. Department of Treasury’s Financial Crimes Enforcement Network (FinCEN) issued a notice of proposed rulemaking ...
SELLAS Life Sciences (SLS) is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results